Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Vitamin D and Cardiovascular Events in Rheumatoid Arthritis

12. Oktober 2016 aktualisiert von: Mette Herly, Odense University Hospital

Association Between Baseline Vitamin D Metabolite Levels and Risk of Cardiovascular Events in Rheumatoid Arthritis Patients. A Cohort Study With Patient-record Evaluated Outcomes.

The aim of the study is to evaluate cardiovascular events during long-term follow-up in Rheumatoid Arthritis. The primary outcome "any cardiovascular event" will be evaluated using systematic audits of patient records, and will be associated to low levels of vitamin D at baseline, to investigate the hypothesis that low levels of vitamin D can be part of a prediction model for cardiovascular disease in Rheumatoid Arthritis.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

Cardiovascular morbidity and mortality is increased in patients with rheumatoid arthritis (RA), and among these patients, the prevalence of hypo-vitaminosis D is high. Low levels of vitamin D have been associated with elevated cardiovascular risk in healthy subjects. The objective of this study is to evaluate the risk of cardiovascular events in patients having low 25OHD-total levels at baseline compared to patients with sufficient levels, in an aggressively treated closed cohort of early-diagnosed RA patients.

The primary outcome will be the proportion of patients with any cardiovascular event, evaluated using systematic journal audits. Logistic regression models will be applied to test the hypothesis that there are more cardiovascular events in patients enrolled with a low level of vitamin D (< 50 nmol/l). Secondarily, Cox regression models, based on survival analysis, will be applied, to determine the extent to which independent variables (including different levels of vitamin D at baseline) predict not only whether a cardiovascular event occur, but also when it will occur.

Studientyp

Beobachtungs

Einschreibung (Tatsächlich)

160

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

Hundred-and-sixty early diagnosed and treatment-naive RA patients, recruited from five Danish University Clinics (Trial Centres) from October 1999 to October 2002

Beschreibung

Inclusion Criteria: Fulfilling ACR1987 (American College of Rheumatology 1987 classification criteria for Rheumatoid Arthritis) criteria for RA, disease duration < 6 months, 2 or more swollen joints and age between 18 and 75 years -

Exclusion Criteria: Glucocorticoid treatment 4 weeks prior to inclusion, previous use of DMARDs, malignancy, diastolic blood pressure > 90 mm Hg, elevated serum creatinine, infections with parvovirus B19, Hepatitis B, C and HIV, and any condition contraindicating the study medication.

-

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
Rheumatoid arthritis patients
Participants in the original, parental trial
Sonstiges: Baseline serum vitamin D level below 50 nmol/l
There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
Sonstiges: Baseline serum vitamin D level at or above 50 nmol/l
There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Cardiovascular event
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Events will be recorded using systematic journal audits. A cardiovascular event will be further subclassified as shown in the secondary outcome measures, but for primary outcome measures; any cardiovascular event, including death, will serve as "an event"
Observed in the time-period from inclusion to October the 10th 2016

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Acute cardiovascular hospitalisation due to Myocardial Ischamia
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016

Non-fatal or fatal myocardial infarction, defined by National and International Guidelines (Thygesen et al. 1581-98).

Fatal myocardial infarction is defined as primary fatal event within 7 days, documented post mortem by autopsy, or by the definition of myocardial infarction according to European Guidelines (Thygesen et al. 1581-98) Death of myocardial infarction as a consequence of medical examination/procedure/surgery will be classified as procedure related death.

Acute Coronary Syndrome (ACS) includes acute ischaemic symptoms with eventual elevation in biomarkers or electrocardiographic changes which does not fulfil the criteria of acute myocardial infarction.

Angina Pectoris. Revascularisation procedures (Percutaneous Coronary Intervention (PCI) or Coronary bypass Graft (CABG).
Observed in the time-period from inclusion to October the 10th 2016
Acute cardiovascular hospitalisation due to hearth failure
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016

Patients with non-elective hospitalisation or death, minimum one overnight stay, with symptoms or findings of heart failure.

Death due to heart failure is defined as escalating heart failure symptoms prior to death.
Observed in the time-period from inclusion to October the 10th 2016
Acute cardiovascular hospitalisation due to stroke
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Cerebral haemorrhage, cerebral thromboembolism, Transitory Cerebral Ischemia (TCI) and others Stroke is defined as abrupt severe neurologic deficits, eventually with computer tomographic (CT) documentation. Death within 14 days after symptom-onset of stroke, and without other obviously reasons, is classified as caused by stroke
Observed in the time-period from inclusion to October the 10th 2016
Acute cardiovascular hospitalisation due to arrhythmias
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Atrial fibrillation or flutter, supraventricular tachycardia and others. Ventricular tachycardia, ventricular fibrillation and others. Death due to arrhythmia requires documentation, e.g. telemetric transcript, pacemaker or electrocardiogram
Observed in the time-period from inclusion to October the 10th 2016
Acute cardiovascular hospitalisation due to Procedure-related cardiovascular event
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Any cardiovascular event within 24 hours after cardiovascular medical examination/procedure/surgery.
Observed in the time-period from inclusion to October the 10th 2016
Acute cardiovascular hospitalisation due to other reasons
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Hospitalisation caused by other cardiovascular events, e.g. pulmonary embolism, rupture of aortic aneurism etc.
Observed in the time-period from inclusion to October the 10th 2016
Acute cardiovascular hospitalisation due to supposed cardiovascular reason
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016

Hospitalisation without any documented non-cardiovascular cause. All deaths which are not defined by the cardiovascular reasons mentioned above, and who are not caused by well-documented non-cardiovascular death.

All deaths without known reason
Observed in the time-period from inclusion to October the 10th 2016
Acute non-cardiovascular hospitalisation due to cancer
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Acute hospitalisation due to cancer
Observed in the time-period from inclusion to October the 10th 2016
Acute non-cardiovascular hospitalisation due to infection
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Acute hospitalisation due to infection
Observed in the time-period from inclusion to October the 10th 2016
Acute non-cardiovascular hospitalisation due to respiratory disease
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Acute hospitalisation due to respiratory disease
Observed in the time-period from inclusion to October the 10th 2016
Acute non-cardiovascular hospitalisation due to trauma
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Acute hospitalisation due to trauma
Observed in the time-period from inclusion to October the 10th 2016
Acute non-cardiovascular hospitalisation due to suicide
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Acute - hospitalisation due to suicide
Observed in the time-period from inclusion to October the 10th 2016
Acute non-cardiovascular hospitalisation due to other reasons
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Acute hospitalisation du to other non-cardiovascular reasons, than those previous mentioned
Observed in the time-period from inclusion to October the 10th 2016
Elective cardiovascular hospitalisation due to myocardial ischemia
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Elective cardiovascular hospitalisation due to arrhythmia
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Elective cardiovascular hospitalisation due to heart failure
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Elective cardiovascular hospitalisation due to other cardiovascular reasons
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to cancer
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to infection
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to respiratory disease
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to trauma
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Elective non-cardiovascular hospitalisation due to suicide
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Observed in the time-period from inclusion to October the 10th 2016
Witnessed, sudden cardiovascular death
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Death is witnessed and abrupt within one hour after symptom-onset
Observed in the time-period from inclusion to October the 10th 2016
Non-witnessed, sudden cardiovascular death
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Non-witnessed death with no obvious non-cardiovascular reasons (found death)
Observed in the time-period from inclusion to October the 10th 2016
Non-sudden cardiovascular death
Zeitfenster: Observed in the time-period from inclusion to October the 10th 2016
Death due to any of the cardiovascular caused previously mentioned, more than one hour after symptom-onset
Observed in the time-period from inclusion to October the 10th 2016

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Odense University Hospital

Mitarbeiter

Pfizer
University of Southern Denmark
Region of Southern Denmark
Odense Patient Data Explorative Network
The Danish Rheumatism Association

Ermittler

  • Studienstuhl: Torkell Ellingsen, MD, Phd, Odense University Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Oktober 1999

Primärer Abschluss (Tatsächlich)

1. Oktober 2016

Studienabschluss (Tatsächlich)

1. Oktober 2016

Studienanmeldedaten

Zuerst eingereicht

12. Oktober 2016

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. Oktober 2016

Zuerst gepostet (Schätzen)

13. Oktober 2016

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

13. Oktober 2016

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

12. Oktober 2016

Zuletzt verifiziert

1. Oktober 2016

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 3-3013-930/1/

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Baseline serum vitamin D level below 50 nmol/l

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Hungary

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren